Dealing by directors

DEALING BY DIRECTORS COMPANIES ACT 1985 SECTIONS 324/329 WE HEREBY INFORM YOU THAT ON 29 OCTOBER 2003 SIR TOM MCKILLOP, A DIRECTOR OF THE COMPANY, EXERCISED OPTIONS OVER ASTRAZENECA PLC USD0.25 ORDINARY SHARES UNDER THE COMPANY'S 1993 SENIOR STAFF SHARE OPTION SCHEME AND 1994 EXECUTIVE SHARE OPTION SCHEME. THE DETAILS OF THE EXERCISES ARE AS FOLLOWS:- NUMBER OF SHARES EXERCIS OVER WHICH E PRICE PERIOD WHEN NAME OF OPTION PER EXERCISABLE DIRECTOR EXERCISED SHARE SIR TOM 1,900 748p 05.4.97- MCKILLOP 04.4.04 SIR TOM 12,424 826p 17.4.97- MCKILLOP 16.8.04 AS A RESULT OF THESE EXERCISES SIR TOM MCKILLOP HOLDS OPTIONS OVER 453,242 ORDINARY SHARES OF ASTRAZENECA PLC. WE ALSO INFORM YOU THAT ON 29 OCTOBER 2003, SIR TOM MCKILLOP SOLD 5,482 ASTRAZENECA PLC USD0.25 ORDINARY SHARES AT AN AVERAGE PRICE OF 2857p PER SHARE TO COVER THE COST OF THE EXERCISES AND TO MEET CERTAIN TAX OBLIGATIONS ARISING FROM THE TRANSACTIONS. FOLLOWING THESE TRANSACTIONS SIR TOM MCKILLOP HAS INCREASED HIS HOLDING IN THE COMPANY BY 8,842 SHARES TO 78,402 SHARES WHICH REPRESENTS APPROXIMATELY 0.005 PER CENT OF THE ISSUED ORDINARY CAPITAL OF THE COMPANY. G H R MUSKER COMPANY SECRETARY 29 OCTOBER 2003 ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/10/30/20031030BIT00240/wkr0001.doc http://www.waymaker.net/bitonline/2003/10/30/20031030BIT00240/wkr0002.pdf

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe